Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507873 | 0.94 | CYP11B1 (0.48) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL30610947 | 0.94 | CYP11B1 (0.48) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL1507947 | 0.93 | CYP11B1 (0.47) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL1508007 | 0.93 | HSP90AA1 (0.50) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL6981310 | 0.84 | HSP90AA1 (0.42) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL8359426 | 0.84 | HSP90AA1 (0.54) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL7189934 | 0.82 | HSP90AA1 (0.42) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL10686007 | 0.81 | AGTR1 (0.54) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 | |
| SCHEMBL4978567 | 0.80 | HSP90AA1 (0.41) | HSP90AA1HSP90B1CYP11B1CYP11B2KMT2A | |
| SCHEMBL7855826 | 0.79 | LMNA (0.59) | CYP19A1HSP90AA1HSP90B1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | claimed |
| US-4937250-A | AROMATASE ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| US-4749713-A | Alpha-heterocycle substituted tolunitriles | CIBA-GEIGY CORPORATION (US) | 1988-06-07 | — | — | US | claimed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-0236940-B3 | Alpha-heterocycle substituted tolunitriles | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| US-5473078-A | Aromatase inhibiting compounds | CIBA-GEIGY CORPORATION (US) | 1995-12-05 | — | — | US | disclosed |
| US-5352795-A | Condensing triazolylmethylbenzonitrile with fluorobenzonitrile under basic conditions using alkali metal alkoxide | CIBA-GEIGY CORPORATION (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0236940-B1 | ALPHA-HETEROCYCLE SUBSTITUTED TOLUNITRILES | CIBA-GEIGY AG (CH) | 1993-09-22 | — | — | EP | disclosed |
| US-5112845-A | Inhibitors of estrogen synthesis, veterinary medicine | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| US-5071861-A | Aromatase enzyme inhibitor; antiestrogens | CIBA-GEIGY CORPORATION (US) | 1991-12-10 | — | — | US | disclosed |
| US-4978672-A | Alpha-heterocyclc substituted tolunitriles | CIBA-GEIGY CORPORATION (US) | 1990-12-18 | — | — | US | disclosed |
| US-4937250-A | AROMATASE ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1990-06-26 | — | — | US | disclosed |
| US-4749713-A | Alpha-heterocycle substituted tolunitriles | CIBA-GEIGY CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
| EP-0236940-A2 | Alpha-heterocycle substituted tolunitriles | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP19A1 1/4885HSP90AA1 3118/4885HSP90B1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.